Goldman Sachs’s BridgeBio Pharma BBIO Stock Holding History

Goldman Sachs’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.98M	Sell	53,500 -6,500	-11%	-$455K	﹤0.01%	4087
2026 Q1	$4.46M	Buy	60,000 +10,000	+20%	+$725K	﹤0.01%	3819
2025 Q4	$3.82M	Buy	+50,000	New	+$3.28M	﹤0.01%	3987
2025 Q3	–	Sell	-45,000	Closed	-$1.94M	–	6337
2025 Q2	$1.94M	Sell	45,000 -20,000	-31%	-$727K	﹤0.01%	4205
2025 Q1	$2.25M	Buy	+65,000	New	+$2.19M	﹤0.01%	4059

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Goldman Sachs's BBIO Position: Q2 2026 in Review

Goldman Sachs reduced its BridgeBio Pharma (BBIO) stake by 4.4% in Q2 2026, selling an estimated $5.82M and leaving 1,814,657 shares worth $135M. The position accounts for 0.01% of the portfolio, ranked #997.

Goldman Sachs first reported a position in BBIO in Q2 2019 and has held it in 29 quarters since. The position peaked at $141M in Q1 2026. 475 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

Goldman Sachs held 1,814,657 shares of BridgeBio Pharma worth $135M as of Q2 2026.
Goldman Sachs sold 83,059 BridgeBio Pharma shares in Q2 2026, an estimated $5.82M.
BridgeBio Pharma made up 0.01% of Goldman Sachs's portfolio in Q2 2026, its #997 holding.
Goldman Sachs first reported a position in BridgeBio Pharma in Q2 2019 and has held it in 29 quarters since.
Goldman Sachs's BridgeBio Pharma position peaked at $141M in Q1 2026.
475 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.